Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man

Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man

Revision 1 of this appendix refers to the addition of point 6 – ‘The role of the pathological Complete Response as an endpoint in neoadjuvant breast cancer studies’ (EMA/CHMP/151853/2014). All other content remains unchanged. For background information please see ‘Concept paper on the need to revise Condition – Specific guidance, Appendix 4 to the guideline on the evaluation of anticancer medic...

Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man

Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man

Committee for Medicinal Products for Human Use (chmp) Draft Guideline on the Evaluation of Anticancer Medicinal Products in Man

Guideline on the evaluation of anticancer medicinal products in man

This guideline replaces guideline / NfG Reference.